netFormulary NHS
Herefordshire & Worcestershire
Medicines and Prescribing Committee
 Search
 Formulary Chapter 13: Skin - Full Chapter
Chapter Links...
 Details...
13.05.03  Expand sub section  Drugs affecting the immune response
Pimecrolimus cream (Elidel® cream)
View adult BNF View SPC online View childrens BNF
Formulary
Amber

In line with NICE TA82; commissioned by the CCG
On recommendation of Dermatology Specialist only; GPs may issue first prescription.

 
Link  NICE TA82 Tacrolimus and pimecrolimus for atopic eczema
 
Tacrolimus ointment (Protopic® ointment)
View adult BNF View SPC online View childrens BNF
Formulary
Amber

In line with NICE TA82; commissioned by the CCG
On recommendation of Dermatology Specialist only; GPs may issue first prescription.

 
Link  NICE TA82 Tacrolimus and pimecrolimus for atopic eczema
 
Cytotoxic Drug Azathioprine tablets
View adult BNF View SPC online View childrens BNF
Formulary
Amber with Shared Care

For initiation by Dermatology Specialist only.

 
 
Ciclosporin capsules (Neoral®)
View adult BNF View SPC online View childrens BNF
Formulary
Amber with Shared Care

For initiation by Dermatology Specialist only.

Note prescribing by brand not necessary for dermatology indications.  For use post transplant see section 8.2.2

 
 
Cytotoxic Drug Methotrexate subcutaneous / tablets
View adult BNF View SPC online View childrens BNF
Formulary
Amber with Shared Care

For initiation by Dermatology Specialist only.

 
 
Mycophenolate mofetil tablets / capsules
View adult BNF View SPC online View childrens BNF
Formulary
Amber with Shared Care

For initiation by Dermatology Specialist only.

For dermatomyocitis, polymyocitis, psoriasis, atopic dermatitis, autoimmune bullous dermatoses incl pemphigus - all unlicensed indications.  For use post transplant see section 8.2.1.

 
Link  Drug Safety Update (Feb 2018): Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients
Link  Drug Safety Update (Dec 2015): Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men
 
Adalimumab
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA146 and TA199; commissioned by the CCG

NHS England commissioned when used Behcets Sydrome, Hiradenitis Suppurativa and Uveitis - Specialist Centre prescribing only

 
Link  NICE TA146 Adalimumab for the treatment of psoriasis
Link  NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
 
Apremilast (Otezla® )
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA419 and TA433; commissioned by the CCG

 
Link  MHRA Drug Safety Update (Jan 17): Apremilast (Otezla®▼): risk of suicidal thoughts and behaviour
Link  NICE TA419 Apremilast for treating moderate to severe plaque psoriasis
Link  NICE TA433 Apremilast for treating active psoriatic arthritis
 
Brodalumab (Kyntheum®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA511; commissioned by the CCG

 
Link  NICE TA511 Brodalumab for treating moderate to severe plaque psoriasis
 
Certolizumab pegol (Cimzia®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA445 and TA574; commissioned by the CCG

 
Link  NICE TA445 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Link  NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis
 
Dimethyl fumarate (Skilarence®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA475; commissioned by the CCG

NHS England is responsible commissioner for Multiple Sclerosis

 
Link  NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis
 
Dupilumab (Dupixent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA534; commissioned by the CCG

NHS England is the responsible commissioner for use in asthma through the IFR process - Specialist Centre prescribing only

 
Link  NICE TA534 Dupilumab for treating moderate to severe atopic dermatitis
 
Etanercept
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA103 and TA199; commissioned by the CCG

 
Link  NICE TA103 Etanercept for the treatment of adults with psoriasis
Link  NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
 
Guselkumab (Tremfya®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA521; commissioned by the CCG

 
Link  NICE TA521 Guselkumab for treating moderate to severe plaque psoriasis
 
Infliximab infusion
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA134 and TA199; commissioned by the CCG

  • NHS England is responsible commissioner for JIA and Crohn's disease in children. 
  • NHS England is responsible commissioner for uveitis, connective tissue disease - interstital lung disease, graft versus host disease, renal, pulmonary sarcoidosis, hidradenitis suppurativa and Behcet's syndrome use through the IFR process - Specialist Centre Prescribing Only.
 
Link  NICE TA134 Infliximab for the treatment of adults with psoriasis
Link  NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
 
Ixekizumab (Taltz®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA442 and TA537; commissioned by the CCG

 
Link  NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis
Link  NICE TA537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
 
Risankizumab (Skyrizi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA596; commissioned by the CCG

 
Link  NICE TA596 Risankizumab for treating moderate to severe plaque psoriasis
 
Secukinumab (Cosentyx®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA350 and TA445; commissioned by the CCG

 
Link  NICE TA350 Secukinumab for treating moderate to severe plaque psoriasis
Link  NICE TA445 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
 
Tildrakizumab (Ilumetri®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA575; commissioned by the CCG

 
Link  NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis
 
Ustekinumab infusion / subcutaneous (Stelara®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE TA180 and TA340; commissioned by the CCG

Commissioned by NHSE when used for Paediatric indications.

 
Link  NICE TA180 Ustekinumab for the treatment of adults with moderate to severe psoriasis
Link  NICE TA340 Ustekinumab for treating active psoriatic arthritis
 
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Secondary care only, not to be prescribed in primary care.   

Amber 2

Specialist initiation with shared care guidance Medicines which should be initiated in secondary care by the specialist with follow-on prescription and monitoring according to a specific Shared Care (SC) Guideline. Prescribing may be continued in primary care in line with a shared care guideline   

Amber with Shared Care

Specialist initiation with shared care guidance Medicines which should be initiated in secondary care by the specialist with follow-on prescription and monitoring according to a specific Shared Care (SC) Guideline. Prescribing may be continued in primary care in line with a shared care guideline   

Amber

Considered suitable for primary care prescribing following specialist initiation/recommendation.  

Green

Considered appropriate for prescribing in both secondary and primary care. Suitable for initiation in primary care.   

netFormulary